Find Perflutren manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

11 RELATED EXCIPIENT COMPANIES

20EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Perfluoropropane, Octafluoropropane, Definity, 76-19-7, Propane, octafluoro-, 1,1,1,2,2,3,3,3-octafluoropropane
Molecular Formula
C3F8
Molecular Weight
188.02  g/mol
InChI Key
QYSGYZVSCZSLHT-UHFFFAOYSA-N
FDA UNII
CK0N3WH0SR

Perflutren
Perflutren Lipid Microspheres is an injectable suspension of liposome-encapsuled microspheres containing the fluorocarbon gas perflutren for contrast enhancement in ultrasound procedures. Because the acoustic impedance of perflutren lipid microspheres is much lower than that of blood, impinging ultrasound waves are scattered and reflected at the microsphere-blood interface and may be visualized with ultrasound imaging.
Perflutren is a Contrast Agent for Ultrasound Imaging. The mechanism of action of perflutren is as an Ultrasound Contrast Activity.
1 2D Structure

Perflutren

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1,1,1,2,2,3,3,3-octafluoropropane
2.1.2 InChI
InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11
2.1.3 InChI Key
QYSGYZVSCZSLHT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C(C(F)(F)F)(C(F)(F)F)(F)F
2.2 Other Identifiers
2.2.1 UNII
CK0N3WH0SR
2.3 Synonyms
2.3.1 MeSH Synonyms

1. C3f8-gas

2. Definity

3. Mrx-115

4. Octafluoropropane

5. Perfluoropropane

2.3.2 Depositor-Supplied Synonyms

1. Perfluoropropane

2. Octafluoropropane

3. Definity

4. 76-19-7

5. Propane, Octafluoro-

6. 1,1,1,2,2,3,3,3-octafluoropropane

7. Freon 218

8. Optison

9. Oktafluorpropan

10. Genetron 218

11. Dmp 115

12. Mrx-115

13. Octafluorpropan

14. 9048-46-8

15. Fc 218

16. Fc 218 (refrigerant)

17. Bovine Serum Albumin

18. Fs069

19. Hfc 218

20. Pfc 218

21. Un 2424

22. Dmp-115

23. R 218

24. Fs-069

25. Ck0n3wh0sr

26. Luminity

27. Chebi:31980

28. Perflutren [usan]

29. Propane, 1,1,1,2,2,3,3,3-octafluoro-

30. C3f8-gas

31. Perflutren Lipid Microsphere

32. Einecs 200-941-9

33. Unii-ck0n3wh0sr

34. Un2424

35. Perflutren Lipid Microspheres

36. Bovine Albumin

37. Perflutren [usan:inn:ban]

38. C3f8

39. Hsdb 8074

40. Octafluoro-propane

41. Definity (tn)

42. Mfcd00039239

43. Optison (salt/mix)

44. Perflutren [ii]

45. Perflutren [inn]

46. Perflutren [jan]

47. Perflutren [vandf]

48. Ec 200-941-9

49. Perflutren-lipid Microsphere

50. Perflutren [mart.]

51. Perflutren Protein-type A Microspheres Injection

52. Chembl1663

53. Perflutren [who-dd]

54. Perfluoropropane [mi]

55. Perflutren (jan/usan/inn)

56. Perflutren [ema Epar]

57. Perfluoropropane [inci]

58. Dtxsid9052503

59. Perflutren [orange Book]

60. Octafluoropropane [vandf]

61. Oxtafluoropropane [vandf]

62. Amy6865

63. Mrx 115

64. Octafluoropropane-lipid Microsphere

65. Ym454

66. Zinc8214651

67. Akos006228213

68. Db00556

69. Fs-6566

70. Octafluoropropaneor Refrigerant Gas R 218

71. Db-056033

72. Ft-0621948

73. Ft-0631321

74. Liposome-encapsulated Perfluoropane Microsphere

75. 1,1,1,2,2,3,3,3-octakis(fluoranyl)propane

76. D01738

77. A838638

78. Q412659

79. Octafluoropropaneor Refrigerant Gas R 218 [un2424] [nonflammable Gas]

2.4 Create Date
2005-03-27
3 Chemical and Physical Properties
Molecular Weight 188.02 g/mol
Molecular Formula C3F8
XLogP33.1
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count8
Rotatable Bond Count0
Exact Mass187.98722530 g/mol
Monoisotopic Mass187.98722530 g/mol
Topological Polar Surface Area0 Ų
Heavy Atom Count11
Formal Charge0
Complexity120
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameDefinity
PubMed HealthPerflutren Lipid Microsphere (Injection)
Drug ClassesRadiological Non-Ionic Contrast Media
Active IngredientPerflutren
Dosage FormInjectable
RouteIntravenous
Strength6.52mg/ml
Market StatusPrescription
CompanyLantheus Medcl

2 of 4  
Drug NameOptison
PubMed HealthPerflutren Protein Type A Microsphere (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Active IngredientAlbumin human
Dosage FormInjectable
RouteInjection
Strength10mg/ml
Market StatusPrescription
CompanyGe Healthcare

3 of 4  
Drug NameDefinity
PubMed HealthPerflutren Lipid Microsphere (Injection)
Drug ClassesRadiological Non-Ionic Contrast Media
Active IngredientPerflutren
Dosage FormInjectable
RouteIntravenous
Strength6.52mg/ml
Market StatusPrescription
CompanyLantheus Medcl

4 of 4  
Drug NameOptison
PubMed HealthPerflutren Protein Type A Microsphere (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Active IngredientAlbumin human
Dosage FormInjectable
RouteInjection
Strength10mg/ml
Market StatusPrescription
CompanyGe Healthcare

4.2 Therapeutic Uses

Contrast Media; Fluorocarbons

National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)


THERAPEUTIC CATEGORY: Diagnostic aid (ultrasound contrast agent). Adjunct in repair of retinal detachment

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006., p. 1236


Activated Perflutren Lipid Microsphere Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


4.3 Drug Warning

/BOXED WARNING/ Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes perflutren-containing microsphere administration. Always have resuscitation equipment and trained personnel readily available.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


Do not administer Perflutren to patients with known or suspected: right-to-left, bi-directional, or transient right-to-left cardiac shunts; hpersensitivity to perflutren. Do not administer Perflutren by intra-arterial injection.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


Serious cardiopulmonary reactions including fatalities have occurred uncommonly during or shortly following perflutren-containing microsphere administration, typically within 30 minutes of administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias). Always have cardiopulmonary resuscitation personnel and equipment readily available prior to Perflutren administration and monitor all patients for acute reactions. The reported reactions include: fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


In postmarketing use, uncommon but serious anaphylactoid reactions were observed during or shortly following perflutren-containing microsphere administration including: Shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema have occurred in patients with no prior exposure to perflutren-containing microsphere products.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


For more Drug Warnings (Complete) data for Octafluoropropane (17 total), please visit the HSDB record page.


4.4 Drug Indication

Used as an ultrasound contrast imaging in cardiology and radiology.


FDA Label


This medicinal product is for diagnostic use only.

Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.


This medicinal product is for diagnostic use only.

Optison is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left-ventricular-endocardial-border delineation with resulting improvement in wall-motion visualisation.

Optison should only be used in patients where the study without contrast enhancement is inconclusive.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. It provide contrast enhancement of the endocardial borders during echocardiography. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.


5.2 MeSH Pharmacological Classification

Contrast Media

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
PERFLUTREN
5.3.2 FDA UNII
CK0N3WH0SR
5.3.3 Pharmacological Classes
Ultrasound Contrast Activity [MoA]; Contrast Agent for Ultrasound Imaging [EPC]
5.4 ATC Code

V08DA04


V08DA01


5.5 Absorption, Distribution and Excretion

Human pharmacokinetics information is not available for the intact or degassed lipid microspheres. The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in healthy subjects (n=8) after the IV administration of activated perflutren-containing microspheres at a 50 uL/kg dose. ... OFP was not detectable after 10 minutes in most subjects either in the blood or in expired air.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


OFP gas binding to plasma proteins or partitioning into blood cells has not been studied. However, OFP protein binding is expected to be minimal due to its low partition coefficient into whole blood.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


It is not known whether perflutren-containing microspheres are excreted in human milk.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


A physiologically based pharmacokinetic model was developed to evaluate the kinetics of one of the newest sonographic contrast agents available, FS069 or Optison. This material consists of octafluoropropane gas encapsulated in proteinaceous microspheres, injected intravenously for use as a myocardial contrast agent in humans. This model has six compartments: two lung compartments (alveolar and dead volume), and compartments for the heart, slowly perfused tissue, richly perfused tissue, and gastrointestinal tract. The model was developed to determine the distribution and excretion of the octafluoropropane in the body. Despite the high affinity of octafluoropropane for tissue, the model predicted that nearly 100% of the material would be exhaled from the lungs within 6 min. The model verified the results of a phase I clinical trial with 10 healthy subjects. Ventilation rate was found to play a critical role in the complete excretion of this contrast agent. ...

PMID:9952073 Hutter JC et al; J Ultrasound Med 18 (1): 1-11 (1999)


5.6 Metabolism/Metabolites

OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.


OFP is a stable gas that is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


5.7 Biological Half-Life

The mean half-life of OFP in blood 1.9 minutes


OFP concentrations in blood were shown to decline in a mono-exponential fashion with a mean half-life of 1.3 minutes in healthy subjects.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


The pharmacokinetics of octafluoropropane gas (OFP) was evaluated in subjects (n=11) with chronic obstructive pulmonary disease (COPD). The mean half-life of OFP in blood was 1.9 minutes. The total lung clearance of OFP was similar to that in healthy subjects.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


5.8 Mechanism of Action

Perflutren is comprised of gas-filled microspheres that are injected or infused into the body. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.


Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated perflutren-containing microspheres provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography.

US Natl Inst Health; DailyMed. Current Medication Information for DEFINITY (perflutren) injection, suspension (October 2011). Available from, as of June 1, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ab9c79c-1b5c-4e86-899c-cc74686f070a


API SUPPLIERS

read-more
read-more

01

Air Liquide Healthcare America Cor...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Air Liquide Healthcare America Cor...

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

FLUOROMED LP

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

FLUOROMED LP

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

03

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Mallinckrodt Pharmaceuticals

Ireland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

AIR PRODUCTS FR 38070 Saint Quenti...

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

AIR PRODUCTS FR 38070 Saint Quenti...

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

ABRAXIS BIOSCIENCE

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

ABRAXIS BIOSCIENCE

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Albumedix

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Albumedix

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

09

Albumedix

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Albumedix

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank

10

Laboratorios Imperiales, S.A. de C...

Mexico

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Duphat
Not Confirmed

02

Duphat
Not Confirmed

03

Duphat
Not Confirmed

03

Duphat
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 11695

Submission : 1995-09-28

Status : Inactive

Type : II

blank

04

Fluoromed Lp

U.S.A

USDMF

arrow
Duphat
Not Confirmed

04

Fluoromed Lp

U.S.A
arrow
Duphat
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12637

Submission : 1997-08-28

Status : Active

Type : II

blank

05

Mallinckrodt Inc

Ireland

USDMF

arrow
Duphat
Not Confirmed

05

Duphat
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12913

Submission : 1998-03-10

Status : Inactive

Type : II

blank

06

Scott Medical Products

Country

USDMF

arrow
Duphat
Not Confirmed

06

Scott Medical Products

Country
arrow
Duphat
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 14405

Submission : 1999-09-14

Status : Inactive

Type : II

blank

07

Flura Corporation

Country

USDMF

arrow
Duphat
Not Confirmed

07

Flura Corporation

Country
arrow
Duphat
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12777

Submission : 1997-12-08

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

Albumedix Limited

United Kingdom
Duphat
Not Confirmed
arrow

Albumedix Limited

United Kingdom
arrow
Duphat
Not Confirmed

Recombumin Prime

Registration Number : 303MF20001

Registrant's Address : Mabel Street, The Meadows, Nottingham, NG2 3ED, United Kingdom

Initial Date of Registration : 2021-03-05

Latest Date of Registration : 2021-03-05

blank

02

Albumedix Limited

United Kingdom
Duphat
Not Confirmed
arrow

Albumedix Limited

United Kingdom
arrow
Duphat
Not Confirmed

Recombumin Elite

Registration Number : 303MF20002

Registrant's Address : Mabel Street, The Meadows, Nottingham, NG2 3ED, United Kingdom

Initial Date of Registration : 2021-03-11

Latest Date of Registration : 2021-03-11

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Perflutren

About the Company : Laboratorios Imperiales, S.A. de C.V. (LISA) is a 72 year old company based in Mexico dedicated to the manufacturing of High Quality Bismuth Salts for use on the pharmaceutical, el...

Laboratorios Imperiales, S.A. de C.V. (LISA) is a 72 year old company based in Mexico dedicated to the manufacturing of High Quality Bismuth Salts for use on the pharmaceutical, electronic, industrial and fine chemicals fields. Laboratorios Imperiales, S.A. De C.V. currently exports its products to the United States, Germany, Latvia and the Russian Federation. The products manufactured by Laboratorios Imperiales are of the highest quality and are currently being consumed by companies such as Kendall, Johnson & Johnson, Nish Pharm and others.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Topical

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Coating Systems & Additives

read-more
read-more

Emulsifying Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Perflutren Manufacturers

A Perflutren manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Perflutren, including repackagers and relabelers. The FDA regulates Perflutren manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Perflutren API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Perflutren manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Perflutren Suppliers

A Perflutren supplier is an individual or a company that provides Perflutren active pharmaceutical ingredient (API) or Perflutren finished formulations upon request. The Perflutren suppliers may include Perflutren API manufacturers, exporters, distributors and traders.

click here to find a list of Perflutren suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Perflutren USDMF

A Perflutren DMF (Drug Master File) is a document detailing the whole manufacturing process of Perflutren active pharmaceutical ingredient (API) in detail. Different forms of Perflutren DMFs exist exist since differing nations have different regulations, such as Perflutren USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Perflutren DMF submitted to regulatory agencies in the US is known as a USDMF. Perflutren USDMF includes data on Perflutren's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Perflutren USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Perflutren suppliers with USDMF on PharmaCompass.

Perflutren JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Perflutren Drug Master File in Japan (Perflutren JDMF) empowers Perflutren API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Perflutren JDMF during the approval evaluation for pharmaceutical products. At the time of Perflutren JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Perflutren suppliers with JDMF on PharmaCompass.

Perflutren KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Perflutren Drug Master File in Korea (Perflutren KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Perflutren. The MFDS reviews the Perflutren KDMF as part of the drug registration process and uses the information provided in the Perflutren KDMF to evaluate the safety and efficacy of the drug.

After submitting a Perflutren KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Perflutren API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Perflutren suppliers with KDMF on PharmaCompass.

Perflutren GMP

Perflutren Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Perflutren GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Perflutren GMP manufacturer or Perflutren GMP API supplier for your needs.

Perflutren CoA

A Perflutren CoA (Certificate of Analysis) is a formal document that attests to Perflutren's compliance with Perflutren specifications and serves as a tool for batch-level quality control.

Perflutren CoA mostly includes findings from lab analyses of a specific batch. For each Perflutren CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Perflutren may be tested according to a variety of international standards, such as European Pharmacopoeia (Perflutren EP), Perflutren JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Perflutren USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty